-
EP3544599
European procedure
Extract from the Register of European Patents
EP About this file: EP3544599
| EP3544599 - BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 23.06.2023 Database last updated on 31.03.2026 | |
| Former | The patent has been granted Status updated on 15.07.2022 | ||
| Former | Grant of patent is intended Status updated on 13.06.2022 | ||
| Former | Examination is in progress Status updated on 17.06.2020 | ||
| Former | Request for examination was made Status updated on 30.08.2019 | ||
| Former | The international publication has been made Status updated on 16.06.2018 | ||
| Former | unknown Status updated on 12.12.2017 | Most recent event Tooltip | 19.12.2025 | Lapse of the patent in a contracting state New state(s): TR | published on 21.01.2026 [2026/04] | Applicant(s) | For all designated states (INSERM) Institut National de la Santé et de la Recherche Médicale 101 rue Tolbiac 75013 Paris / FR | For all designated states Institut national de recherche pour l'agriculture, l'alimentation et l'environnement 147 Rue de l'Université 75007 Paris / FR | For all designated states CNRS Centre National de la Recherche Scientifique 3 Rue Michel Ange 75016 Paris / FR | For all designated states Université de Strasbourg 4, rue Blaise Pascal 67000 Strasbourg / FR | [N/P] |
| Former [2020/43] | For all designated states (INSERM) Institut National de la Santé et de la Recherche Médicale 101 rue Tolbiac 75013 Paris / FR | ||
| For all designated states Institut national de recherche pour l'agriculture, l'alimentation et l'environnement 147 rue de l'Université 75007 Paris / FR | |||
| For all designated states CNRS Centre National de la Recherche Scientifique 3 Rue Michel Ange 75016 Paris / FR | |||
| For all designated states Université de Strasbourg 4, rue Blaise Pascal 67000 Strasbourg / FR | |||
| Former [2019/40] | For all designated states (INSERM) Institut National de la Santé et de la Recherche Médicale 101 rue Tolbiac 75013 Paris / FR | ||
| For all designated states INRA, Institut National de la Recherche Agronomique 147 rue de l'Université 75007 Paris / FR | |||
| For all designated states CNRS Centre National de la Recherche Scientifique 3 Rue Michel Ange 75016 Paris / FR | |||
| For all designated states Université de Strasbourg 4, rue Blaise Pascal 67000 Strasbourg / FR | Inventor(s) | 01 /
ROUX, Sébastien 10 place du Bouc 68150 Ribeauvillé / FR | 02 /
PLOUVIER, Thierry 31 rue du General Faidherbe 37000 Tours / FR | 03 /
LE MERRER, Julie 52 rue du commerce 37110 Monthodon / FR | 04 /
BECKER, Jérôme 15 rue de la Renardière 37360 Semblançay / FR | [2019/40] | Representative(s) | Inserm Transfert PariSanté Campus 10 rue d'Oradour-sur-Glane 75015 Paris / FR | [N/P] |
| Former [2019/40] | Inserm Transfert 7, rue Watt 75013 Paris / FR | Application number, filing date | 17808059.4 | 28.11.2017 | [2019/40] | WO2017EP80726 | Priority number, date | GB20160020095 | 28.11.2016 Original published format: GB 201620095 | [2019/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018096184 | Date: | 31.05.2018 | Language: | EN | [2018/22] | Type: | A1 Application with search report | No.: | EP3544599 | Date: | 02.10.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.05.2018 takes the place of the publication of the European patent application. | [2019/40] | Type: | B1 Patent specification | No.: | EP3544599 | Date: | 17.08.2022 | Language: | EN | [2022/33] | Search report(s) | International search report - published on: | EP | 31.05.2018 | Classification | IPC: | A61K31/138, A61K31/17, A61K31/4418, A61K31/55, A61K31/70, A61K33/00, A61K33/02, A61K33/26, A61P25/20 | [2019/40] | CPC: |
A61K31/70 (EP);
A61K33/00 (EP,US);
A61K31/138 (EP);
A61K31/17 (EP);
A61K31/196 (EP);
A61K31/4418 (EP);
A61K31/496 (EP);
A61K31/519 (EP);
A61K31/522 (EP,US);
A61K31/55 (EP);
A61K31/551 (EP);
A61K38/095 (EP);
| C-Set: |
A61K31/196, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/522, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/40] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | BROMIDQUELLE ZUR VERWENDUNG BEI DER BEHANDLUNG VON ERKRANKUNGEN DES AUTISMUSSPEKTRUMS | [2019/40] | English: | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER | [2019/40] | French: | SOURCE DE BROMURE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN TROUBLE DU SPECTRE AUTISTIQUE | [2019/40] | Entry into regional phase | 29.05.2019 | National basic fee paid | 29.05.2019 | Designation fee(s) paid | 29.05.2019 | Examination fee paid | Examination procedure | 29.05.2019 | Amendment by applicant (claims and/or description) | 29.05.2019 | Examination requested [2019/40] | 29.05.2019 | Date on which the examining division has become responsible | 19.06.2020 | Despatch of a communication from the examining division (Time limit: M04) | 16.10.2020 | Reply to a communication from the examining division | 19.02.2021 | Despatch of a communication from the examining division (Time limit: M04) | 11.06.2021 | Reply to a communication from the examining division | 14.06.2022 | Communication of intention to grant the patent | 12.07.2022 | Fee for grant paid | 12.07.2022 | Fee for publishing/printing paid | 12.07.2022 | Receipt of the translation of the claim(s) | Opposition(s) | 19.05.2023 | No opposition filed within time limit [2023/30] | Fees paid | Renewal fee | 20.11.2019 | Renewal fee patent year 03 | 19.11.2020 | Renewal fee patent year 04 | 18.11.2021 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 28.11.2017 | AL | 17.08.2022 | AT | 17.08.2022 | BG | 17.08.2022 | CY | 17.08.2022 | CZ | 17.08.2022 | DK | 17.08.2022 | EE | 17.08.2022 | FI | 17.08.2022 | HR | 17.08.2022 | LT | 17.08.2022 | LV | 17.08.2022 | MC | 17.08.2022 | MK | 17.08.2022 | MT | 17.08.2022 | NL | 17.08.2022 | PL | 17.08.2022 | RO | 17.08.2022 | RS | 17.08.2022 | SE | 17.08.2022 | SI | 17.08.2022 | SK | 17.08.2022 | SM | 17.08.2022 | TR | 17.08.2022 | NO | 17.11.2022 | GR | 18.11.2022 | IE | 28.11.2022 | LU | 28.11.2022 | BE | 30.11.2022 | CH | 30.11.2022 | LI | 30.11.2022 | IS | 17.12.2022 | PT | 19.12.2022 | [2026/04] |
| Former [2024/42] | HU | 28.11.2017 | |
| AL | 17.08.2022 | ||
| AT | 17.08.2022 | ||
| BG | 17.08.2022 | ||
| CY | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| MK | 17.08.2022 | ||
| MT | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2024/34] | HU | 28.11.2017 | |
| AL | 17.08.2022 | ||
| AT | 17.08.2022 | ||
| BG | 17.08.2022 | ||
| CY | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| MK | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2024/27] | HU | 28.11.2017 | |
| AL | 17.08.2022 | ||
| AT | 17.08.2022 | ||
| CY | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| MK | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2024/21] | HU | 28.11.2017 | |
| AL | 17.08.2022 | ||
| AT | 17.08.2022 | ||
| CY | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2024/18] | HU | 28.11.2017 | |
| AL | 17.08.2022 | ||
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/49] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| BE | 30.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/48] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IE | 28.11.2022 | ||
| LU | 28.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/37] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SI | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| LU | 28.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/35] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| CH | 30.11.2022 | ||
| LI | 30.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/31] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| MC | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/29] | AL | 17.08.2022 | |
| AT | 17.08.2022 | ||
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/23] | AT | 17.08.2022 | |
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| EE | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SK | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/22] | AT | 17.08.2022 | |
| CZ | 17.08.2022 | ||
| DK | 17.08.2022 | ||
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RO | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/21] | DK | 17.08.2022 | |
| FI | 17.08.2022 | ||
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/20] | FI | 17.08.2022 | |
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| SM | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/12] | FI | 17.08.2022 | |
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| IS | 17.12.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/11] | FI | 17.08.2022 | |
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| PL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/10] | FI | 17.08.2022 | |
| HR | 17.08.2022 | ||
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| GR | 18.11.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/09] | FI | 17.08.2022 | |
| LT | 17.08.2022 | ||
| LV | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| NO | 17.11.2022 | ||
| PT | 19.12.2022 | ||
| Former [2023/08] | FI | 17.08.2022 | |
| LT | 17.08.2022 | ||
| NL | 17.08.2022 | ||
| RS | 17.08.2022 | ||
| SE | 17.08.2022 | ||
| NO | 17.11.2022 | Cited in | International search | [XY] WO0038686 (JANSSEN PHARMACEUTICA NV et al.) | [XY] BACHMANN C J ET AL: "Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany", RESEARCH IN DEVELOPMENTAL DISABILITIES 2013 ELSEVIER INC. USA, vol. 34, no. 9, September 2013 (2013-09-01), pages 2551 - 2563, XP002777290, ISSN: 0891-4222 | [XY] KURITA H ED - WOODBURY-SMITH MARC: "Brief report: delusional disorder in a male adolescent with high-functioning PDDNOS", JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, PLENUM PRESS, NEW YORK, NY, US, vol. 29, no. 5, 30 September 1999 (1999-09-30), pages 419 - 423, XP009502699, ISSN: 0162-3257, DOI: 10.1023/A:1023087029274 DOI: http://dx.doi.org/10.1023/A:1023087029274 | [XY] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1978 (1978-01-01), HERMANS W: "Open study with bromperidol in hospitalized chronic schizophrenic patients.", XP002777291, Database accession no. NLM347883 | [XY] HERMANS W: "Open study with bromperidol in hospitalized chronic schizophrenic patients.", ACTA PSYCHIATRICA BELGICA, vol. 78, no. 1, January 1978 (1978-01-01), pages 89 - 95, ISSN: 0300-8967 | [XY] SONIA DOLLFUS ET AL: "Catecholamines in Autistic Disorder: Effects of Amisulpride and Bromocriptine in a Controlled Crossover Study", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, vol. 3, no. 3, 1 January 1993 (1993-01-01), US, pages 145 - 156, XP055440048, ISSN: 1044-5463, DOI: 10.1089/cap.1993.3.145 DOI: http://dx.doi.org/10.1089/cap.1993.3.145 | [XY] SIMON-SORET C ET AL: "Easai de la bromocriptine dans le traitement de l'autiame infantile - [A trial of bromocriptine in the treatment of infantile autism]", PRESSE MEDICALE, PRESSE MEDICALE, PARIS, FR, vol. 16, no. 26, 4 July 1987 (1987-07-04), pages 1286, XP009502700, ISSN: 0755-4982 | [XY] BRYAN H. KING ET AL: "Baseline Factors Predicting Placebo Response to Treatment in Children and Adolescents With Autism Spectrum Disorders : A Multisite Randomized Clinical Trial", JAMA PEDIATRICS, vol. 167, no. 11, 1 November 2013 (2013-11-01), USA, pages 1045, XP055440041, ISSN: 2168-6203, DOI: 10.1001/jamapediatrics.2013.2698 DOI: http://dx.doi.org/10.1001/jamapediatrics.2013.2698 | [XY] ZHANG J ET AL: "Cholinergic modulation of auditory steady-state response in the auditory cortex of the freely moving rat", NEUROSCIENCE, NEW YORK, NY, US, vol. 324, 8 March 2016 (2016-03-08), pages 29 - 39, XP029511889, ISSN: 0306-4522, DOI: 10.1016/J.NEUROSCIENCE.2016.03.006 DOI: http://dx.doi.org/10.1016/j.neuroscience.2016.03.006 | [Y] TENG BRIAN L ET AL: "Reversal of social deficits by subchronic oxytocin in two autism mouse models", NEUROPHARMACOLOGY, vol. 105, 31 December 2015 (2015-12-31), pages 61 - 71, XP029549451, ISSN: 0028-3908, DOI: 10.1016/J.NEUROPHARM.2015.12.025 DOI: http://dx.doi.org/10.1016/j.neuropharm.2015.12.025 | [Y] E LEMONNIER ET AL: "A randomised controlled trial of bumetanide in the treatment of autism in children", TRANSLATIONAL PSYCHIATRY, vol. 2, no. 12, 1 December 2012 (2012-12-01), pages e202, XP055056334, DOI: 10.1038/tp.2012.124 DOI: http://dx.doi.org/10.1038/tp.2012.124 | [Y] SHORVON SIMON D: "Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958.", EPILEPSIA MAR 2009, vol. 50 Suppl 3, March 2009 (2009-03-01), pages 69 - 92, XP002777292, ISSN: 1528-1167 | by applicant | WO9510999 | US6974585 | WO2006048747 | SUZUKI S ET AL., EPILEPSY RES, vol. 19, 1994, pages 89 - 97 | FRIEDLANDER WJ, ARCH NEUROL, vol. 57, 2000, pages 1782 - 1785 | PEARCE JMS: "Bromide, the first effective antiepileptic agen", J NEUROL NEUROSURG PSYCHIATRY, vol. 72, 2002, pages 412 | SHORVON SD: "Treatment of epilepsy in the century of the ILAE", EPILEPSIA, vol. 50, no. 3, 2009, pages 69 - 130 | CARABALLO R ET AL.: "Epilepsy of infancy with migrating focal seizures: Six patients treated with Bromide", SEIZURE, vol. 23, 2014, pages 899 - 902 | HIGURASHI N ET AL.: "PCDH19-related female-limited epilepsy: further details regarding early clinical features and therapeutic efficacy", EPILEPSY RESEARCH, vol. 106, 2013, pages 191 - 199 | ARZIMANOGLOU A: "Dravet syndrome: From electroclinical characteristics to molecular biology", EPILEPSIA, vol. 50, no. 8, 2009, pages 3 - 9 | CHIRON C: "Current therapeutic procedures in Dravet syndrome", DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, vol. 53, no. 2, 2011, pages 16 - 18 | BOOTHE DM ET AL.: "Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, vol. 240, no. 9, 1 May 2012 (2012-05-01), pages 1073 - 1083 | LEMONNIER ET AL., TRANSL PSYCHIATRY, vol. 2, 2012, pages e202 | ALBERT ETHELBERT EBERT; A. EMIL HISS, THE STANDARD FORMULARY, 1900 | H. DRUCKREY; E. MULLER; M. STUHLMANN: "Die Beeinflussung der sedativen Wirkung durch Antipyretika und Coffein", NAUNYN-SCHMIEDEBERGS ARCHIV FIIR EXPERIMENTELLE PATHOLOGIE UND PHARMAKOLOGIE, vol. 185, no. 2-3, 1937, pages 221 - 226 | PHYSIOL. ABST., vol. 22, 1937, pages 1101 | PHARMACEUTICAL ABSTRACTS, vol. IV, no. 9, 1938, pages 434 | "Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS AND WILKINS | ABBEDUTO L; MCDUFFIE A; THURMAN AJ: "The fragile X syndrome-autism comorbidity: what do we really know?", FRONT GENET, vol. 5, 2014, pages 355 | ARGYROPOULOS A; GILBY KL; HILL-YARDIN EL: "Studying autism in rodent models: reconciling endophenotypes with comorbidities", FRONT HUM NEUROSCI, vol. 7, 2013, pages 417 | BARDONI B; DAVIDOVIC L; BENSAID M; KHANDJIAN EW: "The fragile X syndrome: exploring its molecular basis and seeking a treatment", EXPERT REV MOL MED, vol. 8, no. 8, 2006, pages 1 - 16 | BECKER JA; CLESSE D; SPIEGELHALTER C; SCHWAB Y; LE MERRER J; KIEFFER BL: "Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity", NEUROPSYCHOPHARMACOLOGY, vol. 39, no. 9, 2014, pages 2049 - 2060 | BUDIMIROVIC DB; KAUFMANN WE: "What can we learn about autism from studying fragile X syndrome?", DEV NEUROSCI, vol. 33, no. 5, 2011, pages 379 - 394 | CINQUE C; PONDIKI S; ODDI D; DI CERTO MG; MARINELLI S; TROISI A ET AL.: "Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice", TRANS! PSYCHIATRY, vol. 2, 2012, pages el55 | CONSORTIUM TD-BFX: "Fmrl knockout mice: a model to study fragile X mental retardation", CELL, vol. 78, no. 1, 1994, pages 23 - 33 | CRAWLEY JN: "Mouse behavioral assays relevant to the symptoms of autism", BRAIN PATHOLOGY, vol. 17, no. 4, 2007, pages 448 - 459 | D'HOOGE R; NAGELS G; FRANCK F; BAKKER CE; REYNIERS E; STORM K ET AL.: "Mildly impaired water maze performance in male Fmrl knockout mice", NEUROSCIENCE, vol. 76, no. 2, 1997, pages 367 - 376, XP000671536, DOI: doi:10.1016/S0306-4522(96)00224-2 DOI: http://dx.doi.org/10.1016/S0306-4522(96)00224-2 | DEIDDA G; PARRINI M; NASKAR S; BOZARTH IF; CONTESTABILE A; CANCEDDA L: "Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome", NOT MED, vol. 21, no. 4, 2015, pages 318 - 326 | DURAND CM; BETANCUR C; BOECKERS TM; BOCKMANN J; CHASTE P; FAUCHEREAU F ET AL.: "Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders", NOT GENET, vol. 39, no. 1, 2007, pages 25 - 27, XP008138568, DOI: doi:10.1038/ng1933 DOI: http://dx.doi.org/10.1038/ng1933 | EFTEKHARI S; SHAHROKHI A; TSINTSADZE V; NARDOU R; BROUCHOUD C; CONESA M: "Response to Comment on ''Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring", SCIENCE, vol. 346, no. 6206, 2014, pages 176 | GARBUGINO L; CENTOFANTE E; D'AMATO FR: "Early Social Enrichment Improves Social Motivation and Skills in a Monogenic Mouse Model of Autism, the Oprml (-/-) Mouse", NEURAL PLAST, 2016, pages 5346161 | GAVERIAUX-RUFF C; KIEFFER BL: "Opioid receptor genes inactivated in mice: the highlights", NEUROPEPTIDES, vol. 36, no. 2-3, 2002, pages 62 - 71 | GIGLIUCCI V; LEONZINO M; BUSNELLI M; LUCHETTI A; PALLADINO VS; D'AMATO FR: "Region specific up-regulation of oxytocin receptors in the opioid oprml (-/-) mouse model of autism", FRONT PEDIATR, vol. 2, 2014, pages 91 | HARONY-NICOLAS H; DE RUBEIS S; KOLEVZON A; BUXBAUM JD: "Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment", J CHILD NEUROL, vol. 30, no. 14, 2015, pages 1861 - 1870 | HOLMES GL; TIAN C; HERNAN AE; FLYNN S; CAMP D; BARRY J: "Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide", NEUROBIOLOGY OF DISEASE, vol. 77, 2015, pages 204 - 219 | JAMOT L; MATTHES HW; SIMONIN F; KIEFFER BL; RODER JC: "Differential involvement of the mu and kappa opioid receptors in spatial learning", GENES BRAIN BEHAV, vol. 2, no. 2, 2003, pages 80 - 92 | KIDD SA; LACHIEWICZ A; BARBOUTH D; BLITZ RK; DELAHUNTY C; MCBRIEN D ET AL.: "Fragile X syndrome: a review of associated medical problems", PEDIATRICS, vol. 134, no. 5, 2014, pages 995 - 1005 | LOZANO R; HARE EB; HAGERMAN RJ: "Modulation of the GABAergic pathway for the treatment of fragile X syndrome", NEUROPSYCHIATR DIS TREAT, vol. 10, 2014, pages 1769 - 1779 | MAURIN T; ZONGARO S; BARDONI B: "Fragile X Syndrome: From molecular pathology to therapy", NEUROSCI BIOBEHAV REV, vol. 46P2, 2014, pages 242 - 255 | MCNAUGHTON CH; MOON J; STRAWDERMAN MS; MACLEAN KN; EVANS J; STRUPP BJ: "Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome", BEHAV NEUROSCI, vol. 122, no. 2, 2008, pages 293 - 300 | MOLES A; KIEFFER BL; D'AMATO FR: "Deficit in attachment behavior in mice lacking the mu-opioid receptor gene", SCIENCE, vol. 304, no. 5679, 2004, pages 1983 - 1986 | MONTEIRO P; FENG G: "SHANK proteins: roles at the synapse and in autism spectrum disorder", NOT REV NEUROSCI, vol. 18, no. 3, 2017, pages 147 - 157 | ODDI D; CRUSIO WE; D'AMATO FR; PIETROPAOLO S: "Monogenic mouse models of social dysfunction: implications for autism", BEHAV BRAIN RES, vol. 251, 2013, pages 75 - 84, XP028678659, DOI: doi:10.1016/j.bbr.2013.01.002 DOI: http://dx.doi.org/10.1016/j.bbr.2013.01.002 | PADMASHRI R; REINER BC; SURESH A; SPARTZ E; DUNAEVSKY A: "Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome", J NEUROSCI, vol. 33, no. 50, 2013, pages 19715 - 19723 | PECA J; FELICIANO C; TING JT; WANG W; WELLS MF; VENKATRAMAN TN ET AL.: "Shank3 mutant mice display autistic-like behaviours and striatal dysfunction", NATURE, vol. 472, no. 7344, 2011, pages 437 - 442 | PIETROPAOLO S; GUILLEMINOT A; MARTIN B; D'AMATO FR; CRUSIO WE: "Genetic-background modulation of core and variable autistic-like symptoms in Fmrl knock-out mice", PLOS ONE, vol. 6, no. 2, 2011, pages el7073 | ROMERMANN K; FEDROWITZ M; HAMPEL P; KACZMAREK E; TOLLNER K; ERKER T ET AL.: "Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain", NEUROPHARMACOLOGY, vol. 117, 2017, pages 182 - 194, XP029970765, DOI: doi:10.1016/j.neuropharm.2017.02.006 DOI: http://dx.doi.org/10.1016/j.neuropharm.2017.02.006 | ROTSCHAFER SE; TRUJILLO MS; DANSIE LE; ETHELL IM; RAZAK KA: "Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome", BRAIN RES, vol. 1439, 2012, pages 7 - 14 | ROY S; LIU HC; LOH HH: "mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit", BRAIN RESEARCH MOLECULAR BRAIN RESEARCH, vol. 56, no. 1-2, 1998, pages 281 - 283 | ROY S; WATKINS N; HECK D: "Comprehensive analysis of ultrasonic vocalizations in a mouse model of fragile X syndrome reveals limited, call type specific deficits", PLOS ONE, vol. 7, no. 9, 2012, pages e44816 | ROY S; ZHAO Y; ALLENSWORTH M; FAROOK MF; LEDOUX MS; REITER LT ET AL.: "Comprehensive motor testing in Fmrl-KO mice exposes temporal defects in oromotor coordination", BEHAV NEUROSCI, vol. 125, no. 6, 2011, pages 962 - 969 | SILVERMAN JL; YANG M; LORD C; CRAWLEY JN: "Behavioural phenotyping assays for mouse models of autism", NOT REV NEUROSCI, vol. 11, no. 7, 2010, pages 490 - 502 | SPENCER CM; ALEKSEYENKO O; HAMILTON SM; THOMAS AM; SERYSHEVA E; YUVA-PAYLOR LA ET AL.: "Modifying behavioral phenotypes in FmrlKO mice: genetic background differences reveal autistic-like responses", AUTISM RES, vol. 4, no. 1, 2011, pages 40 - 56 | SPENCER CM; ALEKSEYENKO O; SERYSHEVA E; YUVA-PAYLOR LA; PAYLOR R: "Altered anxiety-related and social behaviors in the Fmrl knockout mouse model of fragile X syndrome", GENES BRAIN BEHAV, vol. 4, no. 7, 2005, pages 420 - 430 | TABET R; MOUTIN E; BECKER JA; HEINTZ D; FOUILLEN L; FLATTER E ET AL.: "Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons", PROC NATL ACAD SCI U S A, vol. 113, no. 26, 2016, pages 3619 - 3628, XP002767993, DOI: doi:10.1073/pnas.1522631113 DOI: http://dx.doi.org/10.1073/pnas.1522631113 | VAN DAM D; D'HOOGE R; HAUBEN E; REYNIERS E; GANTOIS I; BAKKER CE ET AL.: "Spatial learning, contextual fear conditioning and conditioned emotional response in Fmrl knockout mice", BEHAV BRAIN RES, vol. 117, no. 1-2, 2000, pages 127 - 136 | VARGHESE M; KESHAV N; JACOT-DESCOMBES S; WARDA T; WICINSKI B; DICKSTEIN DL ET AL.: "Autism spectrum disorder: neuropathology and animal models", ACTA NEUROPATHOLOGICA, 2017 | WOHR M; MOLES A; SCHWARTING RK; D'AMATO FR: "Lack of social exploratory activation in male mu-opioid receptor KO mice in response to playback of female ultrasonic vocalizations", SOC NEUROSCI, vol. 6, no. 1, 2011, pages 76 - 87 | YAN QJ; ASAFO-ADJEI PK; ARNOLD HM; BROWN RE; BAUCHWITZ RP: "A phenotypic and molecular characterization of the fmrl-tmlCgr fragile X mouse", GENES BRAIN BEHAV, vol. 3, no. 6, 2004, pages 337 - 359 |